Nuvectis Pharma to Present Groundbreaking Research at Major Conference
Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical-stage biopharmaceutical company, is excited to announce its participation in the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. This prestigious event will occur from October 22-26, 2025, showcasing innovative research and breakthroughs in oncology. Nuvectis Pharma will prominently feature its lead candidate, NXP900, which is making significant strides in cancer treatment.
Understanding NXP900 and Its Mechanisms
NXP900 serves as a promising oral small molecule inhibitor targeting the SRC Family of Kinases (SFK), specifically SRC and YES1. This innovative therapy offers a multi-faceted approach by inhibiting both the catalytic and scaffolding functions of the SRC kinase, leading to a comprehensive halt in tumor signaling pathways. Through its unique mechanism of action, NXP900 holds potential for treating various malignancies associated with SFK dysregulation.
Clinical Insights and Presentation Details
During the conference, Nuvectis has scheduled two key poster presentations focusing on NXP900. The first poster will detail crucial findings regarding clinical safety, pharmacokinetics, pharmacodynamics, and interactions with cytochrome P450 enzymes associated with NXP900. It will be presented by Dr. Gerald Falchook from the Sarah Cannon Research Institute. Attendees can find this presentation during Poster Session A, scheduled for October 23, 2025, between 12:30 PM and 4 PM ET, listed as Poster Number LB-A019.
Innovations in Tumor Treatment
The second presentation will cover the promising efficacy of NXP900 in inhibiting tumor growth within FAT1 mutated xenograft models. This important research, presented by Asier Unciti-Broceta from the University of Edinburgh, highlights the potential of NXP900 as an effective treatment in clinical settings. This presentation will also take place during Poster Session A on the same date and time, listed under Poster Number A099.
The Importance of Ongoing Research in Oncology
Nuvectis Pharma remains committed to advancing cancer treatment. With NXP900 undergoing a Phase 1a dose escalation study and moving into a Phase 1b clinical program, the potential to change the landscape of cancer therapeutics is significant. The results presented at the conference will not only reflect the innovation behind NXP900 but also the company’s commitment to addressing serious conditions with unmet medical needs.
About Nuvectis Pharma, Inc.
Nuvectis Pharma is driven by its mission to develop innovative precision medicines aimed at treating serious oncological conditions. The current focus on NXP900 exemplifies the company's dedication to pioneering advancements in treatment methods. Additionally, Nuvectis is exploring future developments for NXP800, another oral small molecule currently demonstrating promising anti-cancer activity in challenging cases such as recurrent, platinum-resistant ovarian cancer with ARID1a mutations.
Frequently Asked Questions
What is NXP900?
NXP900 is an oral small molecule inhibitor targeting SRC and YES1 kinases, aimed at treating certain cancers.
When will Nuvectis Pharma present its findings?
Nuvectis will present its findings at the 2025 AACR-NCI-EORTC Conference from October 22-26, with key presentations scheduled for October 23.
Who are the presenters for the NXP900 sessions?
The presentations will be led by Dr. Gerald Falchook and Asier Unciti-Broceta.
What is the significance of the findings on NXP900?
The findings will provide insights into the drug's clinical safety and efficacy, which are crucial for its development in oncology.
Where can I find more information about Nuvectis Pharma?
Additional information can be found by visiting Nuvectis Pharma’s website.
